Hemispherx BioPharma, Inc (NYSEMKT:HEB) declined 4.55% to end last trading session at $0.0840. The company on Nov. 17, 2015 announced its financial results for the nine months ended September 30, 2015. The net loss (including non-cash effects) was approximately $12,093,000 or $(0.05) per share as compared to a net loss of $12,994,000 or ($0.07) per share for the same nine month period in 2014. Cash, cash equivalents and marketable securities were approximately $12,375,000 at September 30, 2015 as compared to $16,108,000 as of December 31, 2014.
Hemispherx Biopharma, Inc. will now collaborate with a new partner, myTomorrows, to provide access to its natural alpha interferon for patients that have become intolerant to treatment with recombinant interferon or where such treatment fails. Through myTomorrows’ Internet-based platform we plan to make this unique interferon formulation available to patients and doctors in Brazil, Columbia and Chile, through an Early Access Program.
Agios Pharmaceuticals Inc (NASDAQ:AGIO) plunged 4.81% to finish last trading session at $61.34. The company on Dec. 18, 2015 announced the initiation of a Phase 1b, multicenter, international, open-label study of AG-221 or AG-120 in combination with induction and consolidation therapy in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are eligible for intensive chemotherapy. AG-221 and AG-120 are first-in-class, oral, selective, potent inhibitors of mutant IDH2 and IDH1, respectively, and are being developed in collaboration with Celgene.
“The five-year survival rate for AML is just 20 to 25 percent, and treatment options for newly diagnosed AML patients have not changed in decades,” said Courtney DiNardo, M.D., lead investigator and assistant professor, department of leukemia at the University of Texas MD Anderson Cancer Center. “By combining a targeted therapy such as AG-221 or AG-120 with standard-of-care intensive chemotherapy in the newly diagnosed setting, we have the potential to provide significant clinical benefit early in the course of treatment.”
Synthetic Biologics Inc (NYSEMKT:SYN) decreased 4.90% to complete last trading session at $2.33. The company on Dec. 8, 2015 announced positive topline results from the four week Phase 2 clinical trial of SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C). “We are pleased to report that SYN-010, a proprietary modified-release formulation of lovastatin lactone, lowered breath methane and improved stool frequency in patients with IBS-C,” stated Joseph Sliman, M.D., MPH, Senior Vice President, Clinical & Regulatory Affairs of Synthetic Biologics. Synthetic Biologics, Inc. is a clinical stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases.